.png "tel(1).png")
+86-591-87519654.png)
South Pharmaceutical is a leading producer of paclitaxel and its intermediates in the Chinese pharmaceutical industry. It is the developer of the national standard "Technical Regulations for the Cultivation of Taxus mairei and Paclitaxel Raw Material Forests in the South," and one of the largest planting bases for Taxus mairei and production bases for paclitaxel and its intermediates in China. The company emphasizes technological innovation and the construction of its research and development team, holding 8 PCT international invention patents and 23 Chinese invention patents.
South Pharmaceutical has a strong sense of social responsibility, focusing on environmental protection and green development. It has a comprehensive environmental management and occupational health and safety management system (EHS system).
福建南方制藥股份有限公司（證券代碼：831207）成立于2001年9月，致力于以紫杉醇原料藥為代表的抗腫瘤藥物的研發(fā)和生產(chǎn)，是一家集藥物種植、研發(fā)、生產(chǎn)、銷售于一體的GMP制藥企業(yè)。公司旗下雪峰、瀚仙兩個(gè)廠區(qū)占地面積共13.1萬平方米，擁有4000畝優(yōu)選南方紅豆杉種植基地。
南方制藥是中國制藥行業(yè)領(lǐng)先的紫杉烷類原料藥及中間體產(chǎn)品生產(chǎn)企業(yè)，是國家標(biāo)準(zhǔn)《南方紅豆杉紫杉醇原料林豐產(chǎn)栽培技術(shù)規(guī)程》的制定者，是中國最大的紅豆杉種植基地和紫杉烷類產(chǎn)品生產(chǎn)供應(yīng)基地之一。公司重視技術(shù)革新和研發(fā)隊(duì)伍的建設(shè)，現(xiàn)有8項(xiàng)PCT國際發(fā)明專利、23項(xiàng)中國發(fā)明專利。
南方制藥富有良好的社會(huì)責(zé)任感，致力于環(huán)境保護(hù)和綠色發(fā)展，擁有完備的環(huán)境管理和職業(yè)健康安全管理體系（EHS體系）。
Fujian South Pharmaceutical Co., Ltd. (Stock Code: 831207) was established in September 2001. It is committed to the research and production of anti-tumor drugs, with paclitaxel as its representative, and is a GMP pharmaceutical enterprise integrating drug planting, research, production, and sales. The company's two factory areas, Xuefeng and Hanxian, cover a total area of 131,000 square meters and have a 4,000-acre high-quality southern yew planting base.
企業(yè)發(fā)展歷程
Enterprise Development History- 2007年
通過國家藥品GMP認(rèn)證
Obtained National Drug GMP Certification
- 2008年
首次通過國家高技術(shù)企業(yè)資格認(rèn)證
First-time accreditation as a National High-Tech Enterprise
- 2014年
旗下南方制藥公司新三板上市（證券代碼：831207）
South Pharmaceutical Company, a subsidiary, listed on the New Third Board (Securities Code: 831207)
- 2016年
通過美國FDA現(xiàn)場審計(jì)
Passed on-site audit by the U.S. Food and Drug Administration (FDA)
- 2017年
榮獲高新技術(shù)企業(yè)、國家林業(yè)重點(diǎn)龍頭企業(yè)等稱號
Honored with titles such as High-Tech Enterprise and National Forestry Key Leading Enterprise
- 2018年
通過歐盟EDQM藥品質(zhì)量認(rèn)證
Passed the European Directorate for the Quality of Medicines & HealthCare (EDQM) certification for drug quality
- 2021年
榮獲國家專精特新“小巨人”企業(yè)稱號
2021: Awarded the title of "National Specialized and Innovative 'Small Giant' Enterprise"
- 2022年
與上海熙華藥業(yè)合作，投資「福建熙華醫(yī)藥產(chǎn)業(yè)園」
Cooperated with Shanghai Xihua Pharmaceutical Industry to invest in the 「Fujian Xihua Pharmaceutical Industrial Park」
.png "畫板 1 拷貝 4(1).png")
.png "畫板 1 拷貝 6(1).png")
.png "畫板 1 拷貝 3(1).png")
.png "畫板 1 拷貝 5(1).png")